美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

AnaptysBio Inc

43.80

0.0000

成交量：- -

成交額：- -

市值：12.59億

市盈率：-95.16

高：43.80

開：43.80

低：43.80

收：43.80

52周最高：49.76

52周最低：41.99

股本：2,874.83萬

流通股本：2,874.83萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.4603

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

AnaptysBio Inc

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.anaptysbio.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

AnaptysBio, Inc.在特拉華成立於2005年11月。該公司是一家專註於為自身免疫性疾病和炎症性疾病提供創新免疫療法的臨床階段生物技術公司。該公司的臨床階段研發管線包括rosnilimab，一種選擇性致病性T細胞清除劑，已完成治療中重度類風濕性關節炎（RA）的IIb期臨床試驗。此外，其研發管線還包括ANB033，一種CD122拮抗劑，目前正在進行治療乳糜瀉（CeD）和嗜酸性粒細胞性食管炎（EoE）的Ib期臨床試驗；以及ANB101，一種BDCA2調節劑，目前正在進行Ia期臨床試驗。AnaptysBio還通過財務合作發現了多種治療性抗體，並將其授權給GSK，包括將PD-1拮抗劑Jemperli（dostarlimab-gxly）授權給GSK，將IL-36R拮抗劑（imsidolimab）授權給Vanda Pharmaceuticals Inc.。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ANABV/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ANABV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANABV\",,,,,undefined,":{"symbol":"ANABV","market":"US","secType":"STK","nameCN":"AnaptysBio Inc","latestPrice":43.8,"timestamp":1781294400000,"preClose":43.8,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":28748255,"shares":28748255,"eps":-0.46027142,"marketStatus":"休市中","change":0,"latestTime":"06-12 16:00:00 EDT","open":43.8,"high":43.8,"low":43.8,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.46027142,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":43.8,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANABV\",,,,,undefined,":{"symbol":"ANABV","floatShares":28748255,"roa":"--","roe":"--","lyrEps":0,"shares":28748255,"dividePrice":0,"high":43.8,"amplitude":0,"preClose":43.8,"low":43.8,"week52Low":41.99,"pbRate":"--","week52High":49.755,"institutionHeld":0,"latestPrice":43.8,"eps":-0.46027142,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.46027142,"open":43.8,"prevYearClose":45.52,"prevWeekClose":43.8,"prevMonthClose":43.8,"prevQuarterClose":45.52,"fiveDayClose":43.8,"twentyDayClose":43.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANABV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-04-20","symbol":"ANABV","reason":null,"defaultRemindTime":1776691800000,"announcedDate":"2026-04-01","type":"delisting","dateTimestamp":1776657600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANABV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ANABV\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3846,"buy":0.5385,"hold":0.0769,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5385,"analysts":13,"updateTime":1767758400000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.anaptysbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":-0.0378},{"period":"ytd","weight":-0.0378}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"AnaptysBio, Inc.在特拉華成立於2005年11月。該公司是一家專註於為自身免疫性疾病和炎症性疾病提供創新免疫療法的臨床階段生物技術公司。該公司的臨床階段研發管線包括rosnilimab，一種選擇性致病性T細胞清除劑，已完成治療中重度類風濕性關節炎（RA）的IIb期臨床試驗。此外，其研發管線還包括ANB033，一種CD122拮抗劑，目前正在進行治療乳糜瀉（CeD）和嗜酸性粒細胞性食管炎（EoE）的Ib期臨床試驗；以及ANB101，一種BDCA2調節劑，目前正在進行Ia期臨床試驗。AnaptysBio還通過財務合作發現了多種治療性抗體，並將其授權給GSK，包括將PD-1拮抗劑Jemperli（dostarlimab-gxly）授權給GSK，將IL-36R拮抗劑（imsidolimab）授權給Vanda Pharmaceuticals Inc.。","exchange":"NASDAQ","name":"AnaptysBio Inc","nameEN":"AnaptysBio Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ANABV\",market:\"US\",,,undefined,":null}}